You just read:

First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models

News provided by

Carisma Therapeutics Inc.

Mar 23, 2020, 12:42 ET